Bullous erysipelas: Clinical presentation, staphylococcal involvement and methicillin resistance

Dermatology

Volumn 212, Issue 1, 2005, Pages 31-35

  Krasagakis, Konstantin ^a   Samonis, George ^a   Maniatakis, Panagiotis ^a   Georgala, Sophia ^b   Tosca, Androniki ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bullous; Erysipelas; Methicillin resistance; Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFPROZILE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; ERYTHROMYCIN; FUSIDIC ACID; MACROLIDE; NETILMICIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; BULLOUS ERYSIPELAS; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE DURATION; ERYSIPELAS; ESCHERICHIA COLI; FACE; FEMALE; FEVER; GREECE; HOSPITAL ADMISSION; HUMAN; INJURY; LEG; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PENICILLIN RESISTANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS WARNERI; STREPTOCOCCUS PYOGENES;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEFUROXIME; CLOXACILLIN; DRUG THERAPY, COMBINATION; ERYSIPELAS; FEMALE; HUMANS; MALE; METHICILLIN; METHICILLIN RESISTANCE; MIDDLE AGED; NETILMICIN; PENICILLINS; SKIN; STAPHYLOCOCCUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 28844487416     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089019     Document Type: Article

References (19)

1. Binnick AN, Klein RB, Baughman RD: Recurrent erysipelas caused by group B streptococcus organisms. Arch Dermatol 1980;116:798-799.
2. Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM: Streptococcal cause of erysipelas and cellulitis in adults - A microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989;125:779-782.
3. Chartier C, Grosshans E: Erysipelas. Int J Dermatol 1990;29:459-467.
4. Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE: Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996;23:1091-1098.
5. Eriksson BK: Anal colonization of group G β-hemolytic streptococci in relapsing erysipelas of the lower extremity. Clin Infect Dis 1999;29:1319-1320.
6. Jorup-Ronstrom C: Epidemiological, bacteriological and complicating features of erysipelas. Scand J Infect Dis 1986;18:519-524.
7. Guberman D, Gilead LT, Zlotogorski A, Schamroth J: Bullous erysipelas: a retrospective study of 26 patients. J Am Acad Dermatol 1999;41:733-737.
8. Smolle J, Kahofer P, Pfaffentaler E, Kerl H: Risk factors for local complications in erysipelas. Hautarzt 2000;51:14-18.
9. Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, Sassolas B, Guillaume JC, Grob JJ, Bastuji-Garin S: Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999;318:1591-1594.
10. Roujeau J-C, Sigurgeirsson B, Korting H-C, Kerl H, Paul C: Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004;209:301-307.
11. Mokni M, Dupuy A, Denguezli M, Dhaoui R, Bouassida S, Amri M, Fenniche S, Zeglaoui F, Doss N, Nouira R, Osman-Dhahri AB, Zili J, Kamoun MR, Zahaf A, Chosidow O: Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study. Dermatology, in press.
12. Hugo-Persson M, Norlin K: Erysipelas and group G streptococci. Infection 1987;15:184-187.
13. Dornbusch K, King A, Legakis N: Incidence of antibiotic resistance in blood and urine isolates from hospitalized patients - Report from a European collaborative study. European Study Group on Antibiotic Resistance (ESGAR). Scand J Infect Dis 1998;30:281-288.
14. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D: Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003;22:406-419.
15. Pantazatou A, Papaparaskevas J, Stefanou I, Papanicolas J, Demertzi E, Avlamis A: Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in a Greek tertiary care hospital, over an 8-year-period. Int J Antimicrob Agents 2003;21:542-546.
16. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus - An emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103-124.
17. Naimi TS, LeDell KH: Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R: Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-2984.
18. Cohen PR, Kurzrock R: Community-acquired methicillin-resistant Staphylococcus aureus infection: an emerging clinical problem. J Am Acad Dermatol 2004;50:277-280.
19. Iyer S, Jones DH: Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004;50:854-858.